Publicacions Institut d’Oncologia de la Cataluntya Sud (IOCS)

Any 2024

Articles:

• Pérez-García JM, Cortés J, Ruiz-Borrego M, Colleoni M, Stradella A, Bermejo B, Dalenc F, Escrivá-de-Romaní S, Calvo Martínez L, Ribelles N, Marmé F, Cortés A, Albacar C, Gebhart G, Prat A, Kerrou K, Schmid P, Braga S, Di Cosimo S, Gion M, Antonarelli G, Popa C, Szostak E, Alcalá-López D, Gener P, Rodríguez-Morató J, Mina L, Sampayo-Cordero M, Llombart- Cussac A; PHERGain Trial Investigators. 3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response- adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial. Lancet. 2024 Apr 27;403(10437):1649-1659. doi: 10.1016/S0140-6736(24)00054- 0. Impact Factor: 54.433, Quartile: Q1.

• Gebhart G, Keyaerts M, Guiot T, Flamen P, Ruiz-Borrego M, Stradella A, Bermejo B, Escriva-de-Romani S, Calvo Martínez L, Ribelles N, Fernandez-Abad M, Albacar C, Colleoni M, Garrigos L, Atienza de Frutos M, Dalenc F, Prat A, Marmé F, Schmid P, Kerrou K, Braga S, Gener P, Sampayo-Cordero M, Cortés J, Pérez-García JM, Llombart-Cussac A. Optimal [18F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial. J Nucl Med. 2024 May 1;65(5):708-713. Impact Factor:: 10.057, Q1.

• Llambrich M, Satorra P, Correig E, Gumà J, Brezmes J, Tebé C, Cumeras R. Easy-Amanida: An R Shiny application for the meta-analysis of aggregate results in clinical metabolomics using Amanida and Webchem. Res Synth Methods. 2024 Mar 13:e1713. doi: 10.1002/jrsm.1713. Epub ahead of print. PMID: 38480474. Impact Factor: 7.216, Quartile: Q1.

• Martínez-Banaclocha N, Martínez-Madueño F, Caballé B, Badia J, Blanes M, Bujanda DA, Calvo V, Gómez Codina J, Blanco CQ, Espinosa P, Lavernia J, Arroyo FRG, Risueño MG, Llorca C, Cumeras R, Pulla MP, Gumà J. A Descriptive Study of 103 Primary Cutaneous B- Cell Lymphomas: Clinical and Pathological Characteristics and Treatment from the Spanish Lymphoma Oncology Group (GOTEL). Cancers (Basel). 2024 Mar 3;16(5):1034. doi: 10.3390/cancers16051034. PMID: 38473391; PMCID: PMC10931196. Impact Factor: 6.6, Quartile: Q1.

• Jiménez-Franco A, Castañé H, Martínez-Navidad C, Placed-Gallego C, Hernández-Aguilera A, Fernández-Arroyo S, Samarra I, Canela-Capdevila M, Arenas M, Zorzano A, Hernández- Alvarez MI, Castillo DD, Paris M, Menendez JA, Camps J, Joven J. Metabolic adaptations in severe obesity: Insights from circulating oxylipins before and after weight loss. Clin Nutr. 2024 Jan;43(1):246-258. doi: 10.1016/j.clnu.2023.12.002. Epub 2023 Dec 6. PMID: 38101315. Impact Factor: 6.1, Quartile: Q1.

• Peressini M, Garcia-Campelo R, Massuti B, Marti C, Cobo M, Gutiérrez V, Dómine M, Fuentes J, Majem M, de Castro J, Cordoba JF, Diz MP, Isla D, Esteban E, Carcereny E, Vila L, Moreno- Vega A, Ros S, Moreno A, Garcia FJ, Huidobro G, Aguado C, Cebey-Lopez V, Valdivia J, Palmero R, Lianes P, Lopez-Brea M, Vidal OJ, Provencio M, Arriola E, Baena J, Herrera M, Bote H, Molero M, Adradas V, Ponce-Aix S, Nuñez-Buiza A, Ucero Á, Hernandez S, Lopez- Rios F, Conde E, Paz-Ares L, Zugazagoitia J. Spatially preserved multi-region transcriptomic subtyping and biomarkers of chemoimmunotherapy outcome in extensive-stage small cell lung cancer. Clin Cancer Res. 2024 Apr 17. doi: 10.1158/1078-0432.CCR-24-0104. Epub ahead of print. PMID: 38630755. Impact Factor: 12.01, Quartile: Q1.

• Torres-Esquius S, Llop-Guevara A, Gutiérrez-Enríquez S, Romey M, Teulé À, Llort G, Herrero A, Sánchez-Henarejos P, Vallmajó A, González-Santiago S, Chirivella I, Cano JM, Graña B, Simonetti S, Díaz de Corcuera I, Ramon Y Cajal T, Sanz J, Serrano S, Otero A, Churruca C, Sánchez-Heras AB, Servitja S, Guillén-Ponce C, Brunet J, Denkert C, Serra V, Balmaña J. Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer. JAMA Netw Open. 2024 Apr 1;7(4):e247811. doi: 10.1001/jamanetworkopen.2024.7811. PMID: 38648056; PMCID: PMC11036141. Impact Factor: 22.5, Quartile: Q1.

• José M. Moreno-Cabrera, Lidia Feliubadaló, Marta Pineda, Patricia Prada-Dacasa, Mireia Ramos-Muntada, Jesús del Valle, Joan Brunet, Bernat Gel, María Currás-Freixes, Bruna Calsina, Milton E. Salazar-Hidalgo, Marta Rodríguez-Balada, Bàrbara Roig, Sara Fernández- Castillejo, Mercedes Durán Domínguez, Mónica Arranz Ledo, Mar Infante Sanz, Adela Castillejo, Estela Dámaso, José L. Soto, Montserrat de Miguel, Beatriz Hidalgo Calero, José M. Sánchez-Zapardiel, Teresa Ramon y Cajal, Adriana Lasa, Alexandra Gisbert-Beamud, Anael López-Novo, Clara Ruiz-Ponte, Miriam Potrony, María I. Álvarez-Mora, Ana Osorio, Isabel Lorda-Sánchez, Mercedes Robledo, Alberto Cascón, Anna Ruiz, Nino Spataro, Imma Hernan, Emma Borràs, Alejandro Moles-Fernández, Julie Earl, Juan Cadiñanos, Ana B. Sánchez-Heras, Anna Bigas. The SpadaHC Consortium, Gabriel Capellá, Conxi Lázaro. SpadaHC: a database to improve the classification of variants in hereditary cancer genes in the Spanish population.22 Database (Oxford). 2024 Jul 4;2024:baae055. PMID: 38965703. Impact Factor: 5.235, Quartile: Q2.

• Anna Pedret, Judit Companys, Lorena Calderón-Pérez, Elisabet Llauradó, Laura Pla-Pagà, Patricia Salamanca, Berner-Andree Sandoval-Ramírez, Úrsula Catalán, Sara Fernández-Castillejo, Silvia Yuste, Alba Macià, Laia Gutiérrez-Tordera, Mónica Bulló, Jordi Camps, Núria Canela, Rosa Maria Valls, Laura Rubió-Piqué, Maria José Motilva, Rosa Solà. A red-fleshed apple rich in anthocyanins improves endothelial function, reduces inflammation, and modulates the immune system in hypercholesterolemic subjects: the AppleCOR study. Food Funct. 2024 Jun 4;15(11):5825-5841. PMID: 38751340.Impact Factor: 4.5, Quartile: Q2.

• Llambrich M, Ramírez N, Cumeras R, Brezmes J. SPME arrow-based extraction for enhanced targeted and untargeted urinary volatilomics. Anal Chim Acta. 2024;1245:343261. doi:10.1016/j.aca.2024.343261.Impact Factor: 7.216, Quartile: Q1.

• Martínez-Banaclocha, N., Martínez-Madueño, F., Caballé, B., Badia, J., Blanes, M., Bujanda, D. A., Calvo, V., Gómez Codina, J., Blanco, C. Q., Espinosa, P., Lavernia, J., Arroyo, F. R. G., Risueño, M. G., Llorca, C., Cumeras, R., Pulla, M. P., & Gumà, J. A descriptive study of 103 primary cutaneous B-cell lymphomas: clinical and pathological characteristics and treatment from the Spanish Lymphoma Oncology Group (GOTEL). Cancers. 2024;16(5):1034. doi:10.3390/cancers16051034.Impact Factor: 6.6, Quartile: Q1.

• Gately L, Mesía C, Sepúlveda JM, Del Barco S, Pineda E, Gironés R, Fuster J, Dumas M, Gill S, Navarro LM, Herrero A, Dowling A, de Las Peñas R, Vaz MA, Alonso M, Lwin Z, Harrup R, Peralta S, Long A, Perez-Segura P, Ahern E, Garate CO, Wong M, Campbell R, Cuff K, Jennens R, Gallego O, Underhill C, Martinez-Garcia M, Covela M, Cooper A, Brown S, Rosenthal M, Torres J, Collins IM, Gibbs P, Balana C. Exploring management and outcomes of elderly patients with glioblastoma using data from two randomised trials (GEINO1401/EX-TEM). J Neurooncol. 2024;168(2):299-306. doi:10.1007/s11060-024-04668-5. Impact Factor: 4.692, Quartile: Q2

• Gately L, Mesía C, Sepúlveda JM, Del Barco S, Pineda E, Gironés R, Fuster J, Hong W, Dumas M, Gill S, Navarro LM, Herrero A, Dowling A, de Las Peñas R, Vaz MA, Alonso M, Lwin Z, Harrup R, Peralta S, Long A, Perez-Segura P, Ahern E, Garate CO, Wong M, Campbell R, Cuff K, Jennens R, Gallego O, Underhill C, Martinez-Garcia M, Covela M, Cooper A, Brown S,23 Rosenthal M, Torres J, Collins IM, Gibbs P, Balana C. A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma. J Neurooncol. 2024;166(2):407-415. doi:10.1007/s11060-023-04513-1. Impact Factor: 4.692, Quartile: Q2.

• Hontecillas-Prieto L, García-Domínguez DJ, Palazón-Carrión N, Martín García-Sancho A, Nogales-Fernández E, Jiménez-Cortegana C, Sánchez-León ML, Silva-Romeiro S, Flores- Campos R, Carnicero-González F, Ríos-Herranz E, de la Cruz-Vicente F, Rodríguez-García G, Fernández-Álvarez R, Martínez-Banaclocha N, Gumà-Padrò J, Gómez-Codina J, Salar- Silvestre A, Rodríguez-Abreu D, Gálvez-Carvajal L, Labrador J, Guirado-Risueño M, Provencio- Pulla M, Sánchez-Beato M, Marylene L, Álvaro-Naranjo T, Casanova-Espinosa M, Rueda- Domínguez A, Sánchez-Margalet V, de la Cruz-Merino L.CD8+ NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B-cell lymphoma. Front Immunol. 2024;15:1293931. doi:10.3389/fimmu.2024.1293931.Impact Factor: 5.749, Quartile: Q1.

• Masvidal Hernandez M, Cros Costa S, Salvador Coloma C, Quilez Cutillas A, Barretina- Ginesta MP, Cotes Sanchís A. First-line PARP inhibitor maintenance treatment in ovarian carcinoma for older adult women: a review of the current literature. Clin Transl Oncol. 2024. doi:10.1007/s12094-024-03609-y. Impact Factor: 3.492, Quartile: Q2.

• GEINO Study Group. Real-world data of IDH mutant gliomas in Spain, a RETSINE: GEINO study. Ann Oncol. 2024;35(5):789-798. doi:10.1016/j.annonc.2024.03.001. Impact Factor: 32.976, Quartile: Q1.

• Maldonado V, Masvidal M, Morente-Laguna V, Cimerman J, Martinez-Soriano S. Atypical Presentation of an Ovarian Yolk Sac Tumor in an 80-Year-Old Woman: A Case Report and Review of the Literature. Case Rep Oncol. 2024;17(1):1342-1350. doi:10.1159/000542244. Impact factor: 0.7, Quartile:Q4

• Di Cosimo S, Pérez-García JM, Bellet M, Dalenc F, Gil Gil MJ, Ruiz-Borrego M, Gavilá J, Aguirre E, Schmid P, Marmé F, Gligorov J, Schneeweiss A, Albanell J, Zamora P, Wheatley D, Martínez de Dueñas E, Amillano K, Shimizu E, Sampayo-Cordero M, Cortés J, Llombart-Cussac A. Impact of coadministration of proton-pump inhibitors and palbociclib in hormone receptor- positive/HER2-negative advanced breast cancer. Breast. 2024 Aug;76:103761. doi:10.1016/j.breast.2024.103761. Epub 2024 Jun 11. PMID: 38880077; PMCID: PMC11228587. Impact Factor: 5.421, Quartile: Q124

• Pérez-García JM, Cortés J, Ruiz-Borrego M, Colleoni M, Stradella A, Bermejo B, Dalenc F, Escrivá-de-Romaní S, Calvo Martínez L, Ribelles N, Marmé F, Cortés A, Albacar C, Gebhart G, Prat A, Kerrou K, Schmid P, Braga S, Di Cosimo S, Gion M, Antonarelli G, Popa C, Szostak E, Alcalá-López D, Gener P, Rodríguez-Morató J, Mina L, Sampayo-Cordero M, Llombart- Cussac A; PHERGain Trial Investigators. 3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response- adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial. Lancet. 2024 Apr 27;403(10437):1649-1659. doi: 10.1016/S0140-6736(24)00054-0. Epub 2024 Apr 3. PMID: 38582092. Impact Factor: 14.325 , Quartile: Q1

• De Angelis R, Demuru E, Baili P, Troussard X, Katalinic A, Chirlaque MD, Innos K, Santaquilani M, Blum M, Ventura L, Paapsi K, Galasso R, Guevara M, Randi G, Bettio M, Botta L, Guzzinati S, Dal Maso L, Rossi S, EUROCARE-6 Working Group. Complete cancer prevalence in Europe in 2020 by disease duration and country (EUROCARE-6): a population-based study. Lancet Oncol. 2024 Mar;25(3):293-307. doi: 10.1016/S1470-2045(23)00646-0. Impact factor: 41.6, Quartile: Q1

• Trama A, Botta L, Stiller C, Visser O, Cañete-Nieto A, Spycher B, Bielska-Lasota M, Katalinic A, Vener C, Innos L, Marcos-Gragera R, Paapsi K, Guevara M, Demuru E, Mohsen Mousavi S, Blum M, Eberle A, Ferrari A, Bernasconi A, Lasalvia P, EUROCARE-6 Working Group. Survival of European adolescents and young adults diagnosed with cancer in 2010-2014. Eur J Cancer. 2024 May:202:113558. doi: 10.1016/j.ejca.2024.113558. Impact factor: 7.6, Quartile: Q1

• Virgili G, Capocaccia R, Botta L, Bennett D, Hadjistilianou T, Innos K, Karim-Kos H, Kuehni C, Kuhnel U, Mazzini C, Cañete A, Paapsi K, Parravano M, Ronckers C, Rossi S, Stiller C, Vicini G, Visser O, Gatta G, EUROCARE-6 Working Group. Survival and Health Care Burden of Children With Retinoblastoma in Europe. JAMA Ophthalmol. 2024 Oct 10;142(11):1062-1070. doi: 10.1001/jamaophthalmol.2024.4140. Impact factor: 8, Quartile: Q1

• Sant M, Vener C, Lillini R, Rossi S, Bonfarnuzzo S, Marcos-Gragera R, Maynadié M, Innos K, Paapsi K, Visser O, Bernasconi A, Demuru E, Di Benedetto C, Mohsen S, Blum M, Went P, Serraino D, Bennett D, Sánchez MJ, De Angelis R, EUROCARE-6 Working Group. Long-term survival for lymphoid neoplasms and national health expenditure (EUROCARE-6): a retrospective, population-based study. Lancet Oncol. 2024 Jun;25(6):731-743. doi:10.1016/S1470-2045(24)00141-4.. Impact factor: 41.6, Quartile: Q1

• Botta L, Capocaccia R, Bernasconi A, Rossi S, Galceran J, Dal Maso L, Lepage C, Molinié F, Bouvier A, Marcos-Gragera R, Vener C, Guevara M, Murray D, Ragusa R, Gatta G, Jooste V, EUROCARE-6 Working Group. Estimating cure and risk of death from other causes of cancer patients: EUROCARE-6 data on Head & Neck, Colorectal, and Breast cancers. Eur J Cancer. 2024 Sep:208:114187. doi: 10.1016/j.ejca.2024.114187. Impact factor: 7.6, Quartile: Q1

• Nguyen NP, Mohammadianpanah M, SunMyint A, Page BR, Vinh-Hung V, Gorobets O, Arenas M, Mazibuko T, Giap H, Vasileiou M, Dutheil F, Tuscano C, Karlsson UL, Dahbi Z, Natoli E, Li25 E, Kim L, Oboite J, Oboite E, Bose S, Vuong T. Immunotherapy and radiotherapy for older patients with locally advanced rectal cancer unfit for surgery or decline surgery: a practical proposal by the International Geriatric Radiotherapy Group. Front Oncol. 2024 Feb 22;14:1325610. doi: 10.3389/fonc.2024.1325610. Impact Factor: 3.5, Quartile: Q2.

• NP Nguyen; ME Chirila; BR Page; V Vinh-Hung; O Gorobets; M Mohammadianpanah; H Giap; M Arenas; M Bonet; PC Lara; L Kim; F Dutheil; D Lehrman; L Zegarra Montes; G Tlili; Z Dahbi; G Loganadane; S Calleja Blanco; S Bose; E Natoli; E Li; A Mallun; AG Morganti. Immunotherapy and stereotactic body radiotherapy for older patients with non-metastatic renal cancer unfit for surgery or decline nephrectomy: practical proposal by the International Geriatric Radiotherapy Group. Frontiers in Oncology. 2024. DOI: 10.3389/fonc.2024.1391464. Impact Factor: 3.5, Quartile: Q2.

• Castro-Larefors S, Marti-Laosa MM, Lopez-Honrubia V, Rey-Lopez I, Ruiz-Herrero B, Murria- Perez Y, Andres I, Jimenez-Garcia IE, Berenguer R, Aguayo-Martos M, Sánchez-Prieto R, Rovirosa A, Jimenez-Jimenez E, Arenas M, Sabater S. Longer time to testosterone recovery impacts favorably on outcomes for prostate cancer following androgen deprivation and radiotherapy. Strahlenther Onkol. 2024 Feb 28. doi: 10.1007/s00066-024-02208-8. Epub ahead of print. PMID: 38416163. Impact Factor: 3.692, Quartile: Q2.

• Sola AB, Otón LF, Guedea F, Arenas M. A nationwide survey of the current status of radiation oncology teaching in Spanish medical schools. Rep Pract Oncol Radiother. 2024 Feb 16;28(6):794-800. doi: 10.5603/rpor.98741. PMID: 38515816; PMCID: PMC10954273. Impact Factor: 3.492, Quartile: Q2

• M Murcia-Mejía; M Canela-Capdevila; R García-Pablo; A Jiménez-Franco; JM Jiménez Aguilar; J Badia; R Benavides-Villarreal; JC Acosta; M Arguis; AI Onoiu; H Castañé; J Camps; M Arenas; J Joven. Combining Metabolomics and Machine Learning to Identify Diagnostic and Prognostic Biomarkers in Patients with Non-Small Cell Lung Cancer Pre- and Post-Radiation Therapy. Biomolecules. 1, Springer, 2024. DOI: 10.3390/biom14080898. Impact Factor: 4,8, Quartile: Q1

• M Arenas; M Fargas-Saladié; M Moreno-Solé; L Moyano-Femenia; A Jiménez-Franco; M Canela-Capdevila; H Castañé; C Martínez-Navidad; J Camps; J Joven. Metabolomics and26 triple-negative breast cancer: A systematic review. Heliyon. 10 - 1, Springer, 2024. DOI: 10.1016/j.clnu.2023.12.002. Impact Factor: 3.4, Quartile: Q1

• A Montero; Meritxell Arenas; C Aristei. SIRARIS: Survey of internal mammary radiotherapy among radiation oncologists from Italy & Spain. Clin Transl Oncol.Springer, 2024. Impact Factor: 3.405, Quartile: Q2

• A Jiménez-Franco; H Castañé; C Martínez-Navidad; C Placed-Gallego; A Hernandez-Aguilera; S Fernandez-Arroyo; I Samarra; M Canela-Capdevila; M Arenas; A Zorzano; MI Hernandez- Alvarez; D Del Castillo; M Paris; JA Menendez; J Camps; J Joven. Metabolic adaptations in severe obesity: Insights from circulating oxylipins before and after weight loss. Clin Nutr. 43 - 1, pp. 246 - 258. Springer, 2024. Impact Factor: 6.6, Quartile: Q1

• Incidence and survival of rare adult solid cancers in Europe (EUROCARE-6): A population-based study. Trama A, Bernasconi A, Cañete A, Carulla M, Daubisse-Marliac L, Rossi S, De Angelis R, Sanvisens A, Katalinic A, Paapsi K, Went P, Mousavi M, Blum M, Eberle A, Lamy S, Capocaccia R, Didonè F, Botta L. Eur J Cancer. 2025 Jan:214:115147. doi: 10.1016/j.ejca.2024.115147. Epub 2024 Nov 27. Impact factor: 7.6

• Cancer Incidence in Five Continents, Vol XII. Bray F, Colombet M, Aitken JF, Bardot A, Eser S, Galceran J, Hagenimana M, Matsuda T, Mery L, Piñeros M, Soerjomataram I, de Vries E, Wiggins C, Won Y-J, Znaor A, Ferlay J, editors (2024).  Lyon: International Agency for Research on Cancer.